Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
Acadia Pharmaceuticals (ACAD) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Catherine Owen Adams will present on January 14, 2025, at 9:00 a.m. PT / 12:00 p.m. ET. The presentation will be available via live webcast on Acadia.com's investor section, with a recording accessible for approximately one month afterward.
Acadia is a neuroscience company that has developed pioneering treatments, including the first FDA-approved drug for Parkinson's disease psychosis-related hallucinations and delusions, and the first approved treatment for Rett syndrome in the US and Canada. The company's clinical-stage pipeline focuses on Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.
Acadia Pharmaceuticals (ACAD) ha annunciato la sua partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan a San Francisco. Il CEO Catherine Owen Adams presenterà il 14 gennaio 2025, alle 9:00 PT / 12:00 ET. La presentazione sarà disponibile tramite webcast dal vivo nella sezione degli investitori di Acadia.com, con una registrazione accessibile per circa un mese dopo.
Acadia è un'azienda attiva nelle neuroscienze che ha sviluppato trattamenti pionieristici, incluso il primo farmaco approvato dalla FDA per le allucinazioni e deliri associati alla psicosi della malattia di Parkinson, e il primo trattamento approvato per la sindrome di Rett negli Stati Uniti e in Canada. Il pipeline in fase clinica dell'azienda si concentra sulla sindrome di Prader-Willi, psicosi da Alzheimer e altri sintomi neuropsichiatrici nei disturbi del SNC.
Acadia Pharmaceuticals (ACAD) ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica J.P. Morgan en San Francisco. La CEO Catherine Owen Adams presentará el 14 de enero de 2025, a las 9:00 a.m. PT / 12:00 p.m. ET. La presentación estará disponible a través de una transmisión en vivo en la sección de inversores de Acadia.com, con una grabación accesible durante aproximadamente un mes después.
Acadia es una empresa de neurociencias que ha desarrollado tratamientos pioneros, incluido el primer medicamento aprobado por la FDA para las alucinaciones y delirios relacionados con la psicosis de la enfermedad de Parkinson, y el primer tratamiento aprobado para el síndrome de Rett en EE. UU. y Canadá. El portafolio en etapa clínica de la empresa se centra en la síndrome de Prader-Willi, psicosis por Alzheimer, y otros síntomas neuropsiquiátricos en trastornos del SNC.
아카디아 제약 (ACAD)이 샌프란시스코에서 열리는 제43회 JP 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO 캐서린 오웬 아담스는 2025년 1월 14일 오전 9시 PT / 오후 12시 ET에 발표를 진행할 예정입니다. 발표는 Acadia.com의 투자자 섹션을 통해 라이브 웹캐스트로 제공되며, 이후 약 한 달 동안 녹화본을 이용할 수 있습니다.
아카디아는 신경 과학 분야의 기업으로, 파킨슨병과 관련된 환각 및 망상 치료를 위한 FDA 승인 최초의 약물과 미국 및 캐나다에서 레트 증후군 치료를 위한 최초 승인 약물을 포함한 혁신적인 치료법을 개발했습니다. 회사의 임상 단계 파이프라인은 프라더-윌리 증후군, 알츠하이머병 환각, 그리고 다른 신경정신증상에 집중하고 있습니다.
Acadia Pharmaceuticals (ACAD) a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan sur la Santé à San Francisco. Le PDG Catherine Owen Adams présentera le 14 janvier 2025, à 9h00 PT / 12h00 ET. La présentation sera disponible via un webinaire en direct dans la section investisseurs d'Acadia.com, avec un enregistrement accessible pendant environ un mois après.
Acadia est une entreprise de neurosciences qui a développé des traitements pionniers, y compris le premier médicament approuvé par la FDA pour les hallucinations et les délires liés à la psychose de Parkinson, ainsi que le premier traitement approuvé pour le syndrome de Rett aux États-Unis et au Canada. Le pipeline de l'entreprise en phase clinique se concentre sur le syndrome de Prader-Willi, la psychose d'Alzheimer et d'autres symptômes neuropsychiatriques dans les troubles du SNC.
Acadia Pharmaceuticals (ACAD) hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference in San Francisco bekannt gegeben. CEO Catherine Owen Adams wird am 14. Januar 2025 um 9:00 Uhr PT / 12:00 Uhr ET präsentieren. Die Präsentation wird über einen Live-Webcast im Anlegerbereich von Acadia.com verfügbar sein, wobei eine Aufzeichnung etwa einen Monat lang zugänglich ist.
Acadia ist ein Unternehmen für Neurowissenschaften, das bahnbrechende Behandlungen entwickelt hat, darunter das erste von der FDA zugelassene Medikament gegen halluzinatorische und wahnhafte Symptome im Zusammenhang mit der Psychose der Parkinson-Krankheit sowie die erste genehmigte Behandlung für das Rett-Syndrom in den USA und Kanada. Die klinische Pipeline des Unternehmens konzentriert sich auf Prader-Willi-Syndrom, Alzheimer-psychosen und andere neuropsychiatrische Symptome bei ZNS-Erkrankungen.
- None.
- None.
A live webcast of Acadia’s presentation will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241219997230/en/
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals
FAQ
When is Acadia Pharmaceuticals (ACAD) presenting at the J.P. Morgan Healthcare Conference 2025?
What are the key therapeutic areas ACAD is currently focusing on in clinical trials?
What breakthrough treatments has ACAD already brought to market?
How can investors access ACAD's J.P. Morgan Healthcare Conference presentation?
What therapeutic areas does ACAD specialize in?
